Novartis files Glivec for approval in rare cancers
Posted on: Monday, 10 April 2006, 00:50 CDT
ZURICH (Reuters) - Novartis has filed for approval from regulators to market its once-a-day cancer pill Glivec for a rare form of skin cancer as well as three kinds of blood disorders, all thought to share the same root.
Glivec, or Gleevec in the United States, was hailed as a breakthrough in cancer treatment when it was launched in late 2002 and is currently approved for use in a form of leukemia and a rare stomach cancer.
Novartis said on Monday it would request approval in the United States and Europe for Glivec in a deep form of skin cancer called dermatofibrosarcoma protuberans, and three forms of blood disorder that have the potential to develop into possibly fatal conditions.
While only a small number of patients are diagnosed with the various conditions for which the Swiss drugmaker is seeking approval, Novartis believes a green light from regulators would lend further validation to concept of targeted cancer therapies.
Source: REUTERS
Related Articles
- Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated By More Than 170 Abstracts at ASCO Annual Meeting
- Bristol-Myers Squibb: High Unmet Need Boosts Ixabepilone's Potential
- Novartis Withdraws Glivec Application
- Novartis Receives Additional EU Approvals for Glivec
- CTI Licenses Lung-Cancer Drug to Novartis
- Novartis Gets FDA OK for New Famvir Indications
- Cancer drug Glivec may harm bones
- Novartis Seeks Gleevac OK in 4 Cancers
- Novartis warns doctors on off-label Femara use
 |
 |
User Comments (0)
RSS Feeds